Jiangxi Sanxin Medtec Co Ltd

Sanxin Medical announced plans to distribute a cash dividend of 1 yuan, tax included, for every 10 shares to all shareholders, with an estimated total payout of 52.19 million yuan. In the first half of 2026, the company achieved revenue of 837 million yuan and net profit attributable to the parent of 132 million yuan.

Sanxin Medical released its 2026 half-year report. Operating revenue was 837 million yuan, up 10.0% year on year. Net profit attributable to the parent was 132 million yuan, up 14.8% year on year. Net profit attributable to the parent after deducting non-recurring items was 122 million yuan, up 17.8% year on year. Net operating cash flow was 155 million yuan, down 17.8% year on year. In the second quarter, operating revenue was 428 million yuan, up 6.9% year on year, and net profit attributable to the parent was 63.76 million yuan, up 3.9% year on year. The company's main business is in the medical device industry, especially in blood purification, drug delivery devices, and cardiothoracic surgery. During the reporting period, revenue from blood purification products increased compared with the same period last year, becoming the core engine of the company's high-quality development.

Sanxin Medical has issued a convertible bond offering announcement, planning to raise up to 530 million yuan, primarily directed toward core segments such as hemodialysis membranes, dialyzers, dialysis tubing, and sterilization support. Among these, 210 million yuan will be allocated to the renovation and expansion project for an annual output of 10 million bundles of hemodialysis membranes and 10 million hemodialyzers, 166 million yuan to the new construction project for an annual output of 30 million sets of hemodialysis tubing and supporting facilities, and 24 million yuan to the renovation and expansion project for the electron accelerator irradiation sterilization production line at Jiangxi Chengtukang. The remaining funds will be used to supplement working capital. The company's products have been selected in multiple provincial alliance centralized procurements, and its domestically first-certified wet-film dialyzer has also entered the supplementary selection catalog. This fundraising project will help the company meet the volume demand from centralized procurement and accelerate overseas business expansion.

The artificial blood vessel product independently developed by Jiangxi Covipeptide Biotechnology, a holding subsidiary of Sanxin Medical, has received approval from the National Medical Products Administration to enter the special review procedure for innovative medical devices. The product uses an integrated expanded polytetrafluoroethylene material, featuring puncture resistance without delamination and excellent biocompatibility. The technological achievement has been listed by the Zhejiang Provincial Department of Science and Technology as one of the major scientific and technological achievements of 2025. After entering this procedure, the product registration application will enjoy priority processing benefits. In the first quarter of 2026, Sanxin Medical achieved revenue of 409 million yuan and a net profit attributable to the parent company of 68.36 million yuan.